Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.

Saved in:
Bibliographic Details
Title: Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
Authors: Kopmar NE; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Quach K; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Gooley TA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Martino CH; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Cherian S; Department of Laboratory Medicine and Pathology, University of Washington, Seattle., Percival MM; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Halpern AB; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Ghiuzeli CM; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Oehler VG; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Abkowitz JL; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Walter RB; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle.; Department of Epidemiology, University of Washington, Seattle., Cassaday RD; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Source: JAMA oncology [JAMA Oncol] 2024 Jul 01; Vol. 10 (7), pp. 961-965.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2374-2445
DOI:10.1001/jamaoncol.2024.0967